Biogen (BIIB) stated that the company "welcomes" the U.S. Veterans Health Administration’s recent decision to provide coverage of Leqembi for veterans living with early stages of Alzheimer’s disease. "Additional details can be found in Eisai’s news release announcing the coverage decision. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority," Biogen stated. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen Appoints Chuck Triano as Head of Investor Relations
- Biogen price target raised to $350 from $335 at RBC Capital
- Needham healthcare analyst to hold an analyst/industry conference call
- No ad com suggests positive potential outcome for Sage’s zura, says BofA
- Biogen elects Dorsa as Chair of the Board of Directors